fda ruling tirzepatide Tirzepatide, FDA, and Compounding: Understanding the Current Landscape Did the FDA Ban Compounded

Note: Compounded medications are prepared based on specific patient needs and are not reviewed or approved by the FDA for safety or effectiveness

The treatment benefit was a reduction in hyperphagia (as measured by a 0-, 5-, or 10-point change on the Hyperphagia Questionnaire for Clinical Trials [HQ-CT])

Pills are likely to be strongest in early treatment, needle-averse patients, maintenance therapy, and broad access markets

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of Cardiology/American heart association task force on practice guidelines and the obesity society

For more information, contact us or book an online appointment